Source:http://linkedlifedata.com/resource/pubmed/id/11605730
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0005558,
umls-concept:C0033572,
umls-concept:C0041618,
umls-concept:C0138741,
umls-concept:C0178587,
umls-concept:C0220908,
umls-concept:C0456603,
umls-concept:C0542559,
umls-concept:C1274040,
umls-concept:C1366489,
umls-concept:C1384593,
umls-concept:C1417779,
umls-concept:C2607943,
umls-concept:C2926606
|
pubmed:issue |
3
|
pubmed:dateCreated |
2001-10-18
|
pubmed:abstractText |
The study offers a retrospective analysis of the positive predictive value (PPV) of several variables, i.e. digital rectal examination (DRE), transrectal ultrasonography (TRUS), PSA value, PSA density (PSAD), and free/total PSA ratio (F/T), for the histologic outcome of 179 prostate biopsies performed within a population-based screening trial. The ratio of spared benign biopsies to missed cancers (SBB/MC) if biopsy results had been decided on the basis of single variables was also evaluated. PPV was 82.9% for DRE, 56.3% for TRUS, 26.6% for PSA (cutoff > or =4 ng/mL), 47.4% for PSA (cutoff > or =10 ng/mL), 42.0% for PSAD (cutoff 0.15), 59.2% for PSAD (cutoff 0.20), 34.9% for F/T (cutoff 0.20) and 40.0% for F/T (cutoff 0.15). SBB/MC was 121/23 for DRE, 96/12 for TRUS, 11/10 for PSA (cutoff > or =4 ng/mL), 107/34 for PSA (cutoff > or =10 ng/mL), 87/23 for PSAD (cutoff 0.15), 109/26 for PSAD (cutoff 0.20), 45/8 for F/T (cutoff 0.20) and 70/14 for F/T (cutoff 0.15). Multivariate analysis of the association with biopsy outcome showed the highest odds ratio for TRUS (13.24, 95% CI=4.4-30.7), and considerably lower values for DRE (4.17, 95% CI=2.0-8-9), PSAD (cutoff 0.20: 3.24, 95% CI=-1.8-5.7) and F/T (cutoff <0.15: 3.16, 95% CI=1.7-1.8). None of the possible variable combinations was clinically useful: the highest PPV (83.3%) was obtained with a combination of suspicious DRE/TRUS, PSAD >0.20 and F/T <0.15, which nevertheless missed 20 of 52 cancers.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0393-6155
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
16
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
179-82
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:11605730-Biopsy,
pubmed-meshheading:11605730-Humans,
pubmed-meshheading:11605730-Male,
pubmed-meshheading:11605730-Physical Examination,
pubmed-meshheading:11605730-Predictive Value of Tests,
pubmed-meshheading:11605730-Prostate,
pubmed-meshheading:11605730-Prostate-Specific Antigen,
pubmed-meshheading:11605730-Prostatic Diseases,
pubmed-meshheading:11605730-Prostatic Neoplasms,
pubmed-meshheading:11605730-Reproducibility of Results,
pubmed-meshheading:11605730-Retrospective Studies,
pubmed-meshheading:11605730-Ultrasonography
|
pubmed:articleTitle |
Predicting prostate biopsy outcome by findings at digital rectal examination, transrectal ultrasonography, PSA, PSA density and free-to-total PSA ratio in a population-based screening setting.
|
pubmed:affiliation |
Centro per lo Studio e la Prevenzione Oncologica, Florence, Italy.
|
pubmed:publicationType |
Journal Article
|